Evaluation of the current knowledge limitations in breast cancer research: A gap analysis

Breast Cancer Research

Volumn 10, Issue 2, 2008, Pages

  Thompson, Alastair ^a   Brennan, Keith ^b   Cox, Angela ^c   Gee, Julia ^d   Harcourt, Diana ^e   Harris, Adrian ^f   Harvie, Michelle ^g   Holen, Ingunn ^c   Howell, Anthony ^h   Nicholson, Robert ^d   Steel, Michael ⁱ   Streuli, Charles ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g WYTHENSHAWE HOSPITAL   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; EVALUATION; EVIDENCE BASED MEDICINE; EXERCISE; FEEDING BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MAMMOGRAPHY; MASS SCREENING; MEDICAL RESEARCH; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PAGET NIPPLE DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNITED KINGDOM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; EXERCISE; FEMALE; FOOD HABITS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; MAMMOGRAPHY; MASS SCREENING; NEOVASCULARIZATION, PATHOLOGIC; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 48949119487     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1983     Document Type: Article

References (125)

1. The CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182. 1182081, 15122511, 10.1086/421251, The CHEK2 Breast Cancer Case-Control Consortium.
2. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Breast Cancer Susceptibility Collaboration (UK) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006, 38:873-875. 10.1038/ng1837, 16832357, Breast Cancer Susceptibility Collaboration (UK).
3. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Breast Cancer Susceptibility Collaboration (UK) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239. 10.1038/ng1902, 17033622, Breast Cancer Susceptibility Collaboration (UK).
4. The Breast Cancer Association Consortium Commonly studied SNPs and breast cancer: negative results from 12,000-32,000 cases and controls from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006, 98:1382-1396. The Breast Cancer Association Consortium.
5. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007, 39:352-358. [Erratum: Nat Genet 2007, 39:688.], 10.1038/ng1981, 17293864.
6. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007, 39:865-869. 10.1038/ng2064, 17529974.
7. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. Genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874. 10.1038/ng2075, 17529973.
8. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J. SEARCH collaborators Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093. 10.1038/nature05887, 17529967, SEARCH collaborators.
9. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386:804-810. 10.1038/386804a0, 9126738.
10. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275. 10.1016/S0092-8674(00)81847-4, 9008167.
11. Polanowska J, Martin JS, Garcia-Muse T, Petalcorin MI, Boulton SJ. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J 2006, 25:2178-2188. 1462971, 16628214, 10.1038/sj.emboj.7601102.
12. Yu X, Fu S, Lai M, Baer R, Chen J. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 2006, 20:1721-1726. 1522068, 16818604, 10.1101/gad.1431006.
13. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609. 10.1126/science.1073834, 12065746.
14. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. Breast Cancer Susceptibility Collaboration (UK) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 17200668, Breast Cancer Susceptibility Collaboration (UK).
15. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274. 10.1126/science.1133427, 16959974.
16. Huang HE, Chin SF, Ginestier C, Bardou VJ, Adélaïde J, Iyer NG, Garcia MJ, Pole JC, Callagy GM, Hewitt SM, Gullick WJ, Jacquemier J, Caldas C, Chaffanet M, Birnbaum D, Edwards PA. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 2004, 64:6840-6844. 10.1158/0008-5472.CAN-04-1762, 15466169.
17. Streuli C, . Ed Key stages of mammary gland development [Review series]. Breast Cancer Res Ed., http://breast-cancer-research.com/articles/review-series.asp?series=bcr_keystages
18. Ip MM, Asch BB. Methods in Mammary Gland Biology and Breast Cancer Research 2000, New York: Kluwer.
19. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88. 10.1038/nature04372, 16397499.
20. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
21. Fowler KJ, Walker F, Alexander W, Hibbs ML, Nice EC, Bohmer RM, Mann GB, Thumwood C, Maglitto R, Danks JA, Chetty R, Burgess AW, Dunn AR. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc Natl Acad Sci USA 1995, 92:1465-1469. 42540, 7533293, 10.1073/pnas.92.5.1465.
22. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 2005, 132:3923-3933. 10.1242/dev.01966, 16079154.
23. Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 2006, 42:441-453. 10.1358/dot.2006.42.7.985637, 16894399.
24. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006, 66:1517-1525. 10.1158/0008-5472.CAN-05-3054, 16452208.
25. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004, 9:119-131. 10.1023/B:JOMG.0000037157.94207.33, 15300008.
26. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006, 11:27-39. 10.1007/s10911-006-9010-8, 16947084.
27. Serra R, Crowley MR. Mouse models of transforming growth factor beta impact in breast development and cancer. Endocr Relat Cancer 2005, 12:749-760. 10.1677/erc.1.00936, 16322320.
28. Watson CJ. Post-lactational mammary gland regression: molecular basis and implications for breast cancer. Expert Rev Mol Med 2006, 8:1-15.
29. Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R. Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res 2007, 9:203. 1851390, 17319974, 10.1186/bcr1651.
30. Sternlicht MD. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 2006, 8:201. 1413974, 16524451, 10.1186/bcr1368.
31. Schwertfeger KL, Rosen JM, Cohen DA. Mammary gland macrophages: pleiotropic functions in mammary development. J Mammary Gland Biol Neoplasia 2006, 11:229-238. 10.1007/s10911-006-9028-y, 17115264.
32. Katz E, Streuli CH. The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol 2006, 39:715-726. 10.1016/j.biocel.2006.11.004, 17251051.
33. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006, 8:1235-1245. 10.1038/ncb1485, 17060907.
34. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24:7443-7454. 10.1038/sj.onc.1209091, 16288291.
35. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006, 8:R7. 1413978, 16417656, 10.1186/bcr1371.
36. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006, 98:1011-1014.
37. Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005, 23:1059-1065. 10.1634/stemcells.2005-0150, 16002779.
38. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006, 16:60-64. 10.1016/j.gde.2005.12.008, 16377171.
39. Green KA, Streuli CH. Apoptosis regulation in the mammary gland. Cell Mol Life Sci 2004, 61:1867-1883. 10.1007/s00018-004-3366-y, 15289930.
40. Watson CJ. Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res 2006, 8:203. 1557708, 16677411, 10.1186/bcr1401.
41. Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell 2006, 9:151-153. 10.1016/j.ccr.2006.02.026, 16530699.
42. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96.
43. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688. 10.1038/nrc1695, 16148884.
44. Clarke RB. Isolation and characterization of human mammary stem cells. Cell Prolif 2005, 38:375-386. 10.1111/j.1365-2184.2005.00357.x, 16300651.
45. Wolf K, Friedl P. Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol 2006, (Suppl 1):11-15.
46. Sidani M, Wyckoff J, Xue C, Segall JE, Condeelis J. Probing the microenvironment of mammary tumors using multiphoton microscopy. J Mammary Gland Biol Neoplasia 2006, 11:151-163. 10.1007/s10911-006-9021-5, 17106644.
47. Hennighausen L, Robinson GW. Information networks in the mammary gland. Nat Rev Mol Cell Biol 2005, 6:715-725. 10.1038/nrm1714, 16231422.
48. Teulière J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 2005, 132:267-277. 10.1242/dev.01583, 15590737.
49. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209. 10.1016/j.ccr.2005.07.009, 16169465.
50. DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999, 126:4557-4568.
51. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004, 101:4966-4971. 387357, 15051869, 10.1073/pnas.0401064101.
52. Rennstam K, Hedenfalk I. High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. Breast Cancer Res 2006, 8:213. 1779477, 16895590, 10.1186/bcr1528.
53. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170. 10.1016/S0092-8674(00)81333-1, 8861899.
54. Sims AH, Ong KR, Clarke RB, Howell A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Res 2006, 8:214. 1779487, 17076877, 10.1186/bcr1605.
55. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005, (Suppl 1):10-20.
56. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006, 96:131-146. 10.1007/s10549-005-9070-2, 16261397.
57. Speirs V, Walker RA. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol 2007, 211:499-506. 10.1002/path.2130, 17236182.
58. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 2005, (Suppl 1):S29-36.
59. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3:51-62. 10.1016/S1535-6108(02)00235-0, 12559175.
60. Sledge GW. VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 2005, 10:319-323. 10.1007/s10911-006-9005-5, 16924373.
61. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 2004, 21:201-212. 10.1023/B:CLIN.0000037697.76011.1d, 15387370.
62. Jones JL, JA S, JH P, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003, 201:562-572. 10.1002/path.1483, 14648659.
63. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in Tenascin-C isoforms expression in invasive and preinvasive breast disease. Cancer Res 2002, 62:3289-3297.
64. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006, 94:253-258. 10.1038/sj.bjc.6602932, 16421596.
65. Kamb A. What's wrong with our cancer models?. Nat Rev Drug Discov 2005, 4:161-165. 10.1038/nrd1635, 15688078.
66. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 2006, 8:R32. 1557729, 16790077, 10.1186/bcr1506.
67. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006, 5:135-142. 10.1007/s10689-005-2832-5, 16736282.
68. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J, . for the Scandinavian Breast Group Trial 9401 Topoisomerase II alpha gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006, 24:2428-2436. 10.1200/JCO.2005.02.9264, 16682728, for the Scandinavian Breast Group Trial 9401.
69. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005, (Suppl 1):S99-S111.
70. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC, Ali S. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 2006, 13:851-861. 10.1677/erc.1.01123, 16954434.
71. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000, 53:634-635. 1762930, 11002770, 10.1136/jcp.53.8.634.
72. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R. Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004, 57:233-237. 1770242, 14990588, 10.1136/jcp.2003.007724.
73. Walker RA. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006, 49:406-410. 10.1111/j.1365-2559.2006.02514.x, 16978204.
74. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
75. Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. Deciphering anti hormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 2006, (Suppl 1):S77-88.
76. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The anti-epidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117. 10.1210/en.2003-0705, 12960029.
77. Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer 2006, (Suppl 1):S89-97.
78. Tiligada E, Miligkos V, Delitheos A. Cross-talk between cellular stress, cell cycle and anticancer agents: mechanistic aspects. Curr Med Chem Anticancer Agents 2002, 2:553-566. 10.2174/1568011023353976, 12678735.
79. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003, 159:283-300. 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2, 12600231.
80. Rodger A, Stebbing J, Thompson AM. Breast cancer (non-metastatic). Clin Evid 2006, 15:2360-2392.
81. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, . Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737, Herceptin Adjuvant (HERA) Trial Study Team.
82. Dixon JM. The scientific value of preoperative studies and how they can be used to identify biomarkers. Breast Cancer Res Treat 2004, 87:S19-S26. 10.1007/s10549-004-1579-2, 15597217.
83. Purdie CA. Sentinel lymph node biopsy: review of the literature and guidelines for pathological handling and reporting. Curr Diagn Pathol 2007, 13:106-115.
84. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M, . TRANSBIG consortium TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006, 3:540-551. 10.1038/ncponc0591, 17019432, TRANSBIG consortium.
85. Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D, Bell J, Elston CW, Robertson JF, Blamey RW, Ellis IO. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin fixed tissue samples. Hum Pathol 1995, 26:291-294. 10.1016/0046-8177(95)90060-8, 7890280.
86. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S. Repeated observations of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
87. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116:340-350. 10.1002/ijc.21004, 15818618.
88. Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Magee H, Barnett S, Miller K. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol 2007, 60:816-819. 10.1136/jcp.2006.040840, 16963466.
89. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. 10.1016/S0140-6736(05)74803-0, 15639680.
90. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, . National Surgical Adjuvant Breast and Bowel Project (NSABP) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741. 10.1001/jama.295.23.joc60074, 16754727, National Surgical Adjuvant Breast and Bowel Project (NSABP).
91. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003, 40:807-814. 10.1136/jmg.40.11.807, 14627668.
92. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:1159-1169. 10.1158/1055-9965.EPI-06-0034, 16775176.
93. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981, 66:1191-1308.
94. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are imprecise methods obscuring a relation between fat and breast cancer?. Lancet 2003, 362:212-214. 10.1016/S0140-6736(03)13913-X, 12885485.
95. Freedman LS, Potischman N, Kipnis V, Midthune D, Schatzkin A, Thompson FE, Troiano RP, Prentice R, Patterson R, Carroll R, Subar AF. A comparison of two dietary instruments for evaluating the fat-breast cancer relationship. Int J Epidemiol 2006, 35:1011-1021. 10.1093/ije/dyl085, 16672309.
96. Low YL, Dunning AM, Dowsett M, Luben RN, Khaw KT, Wareham NJ, Bingham SA. Implications of gene-environment interaction in studies of gene variants in breast cancer: an example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene. Cancer Res 2006, 66:8980-8983. 10.1158/0008-5472.CAN-06-2432, 16982738.
97. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005, 14:656-661. 10.1158/1055-9965.EPI-04-0001, 15767346.
98. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006, 296:193-201. 10.1001/jama.296.2.193, 16835425.
99. Harvie M, Howell A. Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. Obes Rev 2006, 7:33-47. 10.1111/j.1467-789X.2006.00207.x, 16436101.
100. International Agency for Research on Cancer Expert Group Breast Cancer Screening. IARC Handbooks of Cancer Prevention 2002, 7:248. Lyon, France: IARC, International Agency for Research on Cancer Expert Group.
101. Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A. Screening younger women with a family history of breast cancer - does early detection improve outcome?. Eur J Cancer 2006, 42:1385-1390. 10.1016/j.ejca.2006.01.055, 16750910.
102. Gui GP, Kadayaprath G, Darhouse N, Self J, Ward A, A'Hern R, Eeles R. Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. Eur J Surg Oncol 2006, 32:719-724. 10.1016/j.ejso.2006.05.002, 16784834.
103. Cortesi L, Turchetti D, Marchi I, Fracca A, Canossi B, Rachele B, Silvia R, Rita PA, Pietro T, Massimo F. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer 2006, 6:210. 1578585, 16916448, 10.1186/1471-2407-6-210.
104. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769-1778. 10.1016/S0140-6736(05)66646-9, 15910949.
105. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005, 23:1370-1378. 10.1200/JCO.2005.01.079, 15684320.
106. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 1990, 8:1327-1334.
107. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003, 95:1467-1476.
108. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006, 98:1767-1776.
109. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA 2005, 293:2479-2486. 10.1001/jama.293.20.2479, 15914748.
110. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 2006, 175:34-41. 1482759, 16818906.
111. Julian-Reynier C, Welkenhuysen M, Hagoel L, Decruyenaere M, Hopwood P, . CRISCOM Working Group Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet 2003, 11:725-736. 10.1038/sj.ejhg.5201037, 14512961, CRISCOM Working Group.
112. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004, 4:CD002748.
113. Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology 2005, 14:917-938. 10.1002/pon.904, 15786514.
114. Brennan J, Moynihan C. Cancer in Context: A Practical Guide to Supportive Care 2004, Oxford: Oxford University Press.
115. Wagner CD, Bigatti SM, Storniolo AM. Quality of life of husbands of women with breast cancer. Psychooncology 2006, 15:109-120. 10.1002/pon.928, 15852406.
116. Moyer A. Psychological outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol 1997, 16:284-298. 10.1037/0278-6133.16.3.284, 9152708.
117. Harcourt DM, Rumsey NJ, Ambler NR, Cawthorn SJ, Reid CD, Maddox PR, Kenealy JM, Rainsbury RM, Umpleby HC. The psychological impact of mastectomy with or without immediate breast reconstruction: a prospective, multi-centred study. Plast Reconstr Surg 2003, 111:1060-1068. 10.1097/01.PRS.0000046249.33122.76, 12621175.
118. Scott JT, Harmsen M, Prictor MJ, Entwistle VA, Sowden AJ, Watt I. Recordings or summaries of consultations for people with cancer. Cochrane Database Syst Rev 2003, 2:CD001539.
119. Fallowfield L, Jenkins V, Farewell V, Solis-Trapala I. Enduring impact of communication skills training: results of a 12-month follow-up. Br J Cancer 2003, 89:1445-1449. 10.1038/sj.bjc.6601309, 14562015.
120. Main DS, Nowels CT, Cavender TA, Etschmaier M, Steiner JF. A qualitative study of work and work return in cancer survivors. Psychooncology 2005, 14:992-1004. 10.1002/pon.913, 15744780.
121. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 2006, 175:34-41. 1482759, 16818906.
122. Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999, 80:1770-1780. 10.1038/sj.bjc.6690596, 10468295.
123. Corner J, Wright D, Foster C, Gunaratnam Y, Hopkinson J, Okamoto I. The Macmillan Listening Study: Listening to the Views of People Affected by Cancer about Cancer Research. Published Report 2006, London: Macmillan Cancer Support.
124. Schofield P, Carey M, Bonevski B, Sanson-Fisher R. Barriers to the provision of evidence-based psychosocial care in oncology. Psychooncology 2006, 15:863-872. 10.1002/pon.1017, 16381066.
125. Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, Galvin E, Decker V. Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol 2002, 20:4050-4064. 10.1200/JCO.2002.02.054, 12351603.